2008-07-23 04:06:09 -

www.admetrx.com - ADMETRx, a Michigan-based privately held Contract Research Organization (CRO) that provides customized solutions to the pharmaceutical and biotechnology industries in making preclinical drug candidate advancement decisions, announced that company co-founder, Philip S. Burton, PhD, has accepted an appointment to the advisory board of Locus Pharmaceuticals. With 25 years of experience in medicinal and biopharmaceutical chemistry

and drug absorption, Dr. Burton, also the CEO and CSO of ADMETRx, is an internationally recognized thought-leader in modeling drug absorption and a frequent invited lecturer to numerous national and international symposia.

"Dr. Burton and the team at ADMETRx bring to the Locus Advisory Board a broad and deep understanding of the impact of ADME and pharmacokinetics upon advancing successful drug discovery candidates," says Jeff Wiseman, PhD, Chief Technology Officer at Locus Pharmaceuticals. "We feel that Dr. Burton will be a key advisor to our drug discovery and development programs as we move our internal projects into clinical trials."

ADMETRx was founded by Dr. Burton and co-founder Jay T. Goodwin, PhD (company President and COO) in 2003. Committed to redefining the drug discovery process, ADMETRx assists pharma and biotech clients in optimizing their lead selection decision-making. Focusing specifically on the ADME research needs of their customers, the company addresses a wide range of relevant issues, from managing capacity challenges to developing sophisticated multi-criteria optimization approaches. Its high quality data integration via advanced techniques and technologies leads to cost savings and improved drug discovery effectiveness.

Locus Pharmaceuticals is also a privately held company that was founded as Locus Discovery in 1999. A world leader in computational drug design, the company's core technology is a fragment-based, computational approach, which it has combined with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform. Locus is using its capabilities to develop its own compounds and has also entered into drug design/development collaborations with several pharma and biotech partners.

Committed to assisting their clients achieve their drug discovery goals, both ADMETRx and Locus Pharmaceuticals have dynamic leadership teams composed of scientific experts and business leaders who have longstanding experience and success in the pharmaceutical and biotechnology industries.

ADMETRx
Jay T. Goodwin, PhD
269-372-3272
jtgoodwin@admetrx.com
www.admetrx.com